Financials Results for the quarter ended on 30thu June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kapil Cotex Limited (BSE: 512036) submitted its unaudited financial results for the quarter ended 30 June 2025. On a standalone basis, profit after tax rose sharply to Rs 25.44 lakhs from Rs 5.96 lakhs in the same quarter last year, with total income at Rs 35.42 lakhs versus Rs 18.12 lakhs. On a consolidated basis, total income jumped to Rs 242.28 lakhs from Rs 35.42 lakhs, driven almost entirely by its subsidiary Skybiotech Life Sciences Private Limited, which contributed Rs 239.32 lakhs in revenue. However, consolidated expenses of Rs 244.15 lakhs pushed the group into a small loss of Rs (1.87) lakhs, compared to a profit of Rs 25.44 lakhs a year ago. The auditor (SPD & Associates) issued an unqualified limited review report with no qualifications or emphasis of matter.
Strong top-line growth from the newly consolidated Skybiotech subsidiary, but margin pressure on a group level as expenses exceeded revenue, resulting in a small consolidated loss. Standalone operations remain profitable and improving.